Corporate History

Our Corporate Developement

1997 Company founded in China to engage in the research, development, production, marketing and sales of veterinary healthcare and medical care products in People’s Republic of China (PRC China)

2005 Skystar begins to trade publicly via reverse merger in the United States on the over-the-counter bulletin board (OTCBB), becomes the first stand alone China animal health pureplay listed in the U.S.

2009 Stock listing is transferred to NASDAQ and begins trading under the symbol “SKBI,” remaining the only China animal health pureplay listed in the U.S

Skystar closes $20 million financing for manufacturing facility expansion

Skystar acquires exclusive aquaculture vaccine technology and all rights to sell vaccine in China through 2024

2010 Expands production potential by acquiring Jingzhou veterinary medicine manufacturing facility

2011 Acquires Kunshan probiotic manufacturing facility

2012 Veterinary medication manufacturing resumes production following Ministry of Agriculture’s 2011 restructuring of veterinary health manufacturing and inspection standards in China

2014 Skystar’s vaccine manufacturing receives GMP certification following Ministry of Agriculture new standards